Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis.
复制标题
DOI：
10.1038/s41569-021-00629-x
复制
发表时间：
2022-04
期刊：
影响因子：
--
通讯作者：
Tao W
中科院分区：
文献类型：
--
作者：
Chen W;Schilperoort M;Cao Y;Shi J;Tabas I;Tao W
纳米技术可以提高我们对动脉粥样硬化病理生理学的理解，并有助于开发新的诊断和治疗策略，以进一步降低心血管疾病的风险。巨噬细胞在动脉粥样硬化进展中起关键作用，因此，巨噬细胞相关的病理过程是动脉粥样硬化诊断成像和新疗法的重要靶点。在这篇综述中，我们强调了在过去二十年中开发成像技术和使用合理设计的纳米颗粒治疗性操纵动脉粥样硬化斑块中的巨噬细胞的努力。我们回顾了基于纳米颗粒的成像模式，可以特异性地针对巨噬细胞的最新进展。使用新的分子成像技术，这些模式能够识别晚期动脉粥样硬化斑块和评估医疗干预的治疗效果。此外，我们提供了新的观点，如何巨噬细胞靶向纳米粒子可以提供广泛的治疗有效载荷动脉粥样硬化病变。这些纳米颗粒可以抑制促动脉粥样硬化的巨噬细胞过程，从而改善炎症的消退和斑块的稳定。最后，我们提出了新的诊断和治疗策略的未来机会，并提供解决方案，在这一领域的挑战，以加速临床翻译的纳米医学治疗动脉粥样硬化性血管疾病的目的。在这篇综述中，Tao及其同事讨论了靶向动脉粥样硬化斑块中巨噬细胞的基于纳米颗粒的成像和治疗方法的最新进展，强调了用于动脉粥样硬化诊断和治疗的新型巨噬细胞靶向纳米药物的机会，并提供了该领域挑战的解决方案，以加速临床转化。由于巨噬细胞在动脉粥样硬化进展中具有关键作用，因此巨噬细胞介导的促动脉粥样硬化过程是动脉粥样硬化诊断成像和新疗法的重要靶点。纳米技术在其显著改善用于动脉粥样硬化管理的胶囊化诊断和治疗剂的药代动力学特征和化学稳定性的能力方面是特别有利的。基于纳米颗粒的成像剂的合理设计可以特异性靶向动脉粥样硬化斑块中的炎性巨噬细胞，提供了无创量化动脉粥样硬化斑块负荷的诊断潜力，评估医疗干预的疗效，并作为替代终点。通过激活或抑制特定信号传导途径来调节斑块巨噬细胞功能的靶向纳米治疗剂在临床前模型中显示出很大的前景，可以提高治疗效果并减少脱靶和全身不良反应。纳米技术和生物工程的快速发展以及对动脉粥样硬化病理生理学的更好理解加速了用于动脉粥样硬化诊断和治疗的新型纳米治疗剂的开发。各种基于纳米医学的方法在动脉粥样硬化临床前研究中的成功及其在人类癌症中的应用预示着它们在心血管疾病患者诊断和治疗中的未来应用。
Nanotechnology could improve our understanding of the pathophysiology of atherosclerosis and contribute to the development of novel diagnostic and therapeutic strategies to further reduce the risk of cardiovascular disease. Macrophages have key roles in atherosclerosis progression and, therefore, macrophage-associated pathological processes are important targets for both diagnostic imaging and novel therapies for atherosclerosis. In this Review, we highlight efforts in the past two decades to develop imaging techniques and to therapeutically manipulate macrophages in atherosclerotic plaques with the use of rationally designed nanoparticles. We review the latest progress in nanoparticle-based imaging modalities that can specifically target macrophages. Using novel molecular imaging technology, these modalities enable the identification of advanced atherosclerotic plaques and the assessment of the therapeutic efficacy of medical interventions. Additionally, we provide novel perspectives on how macrophage-targeting nanoparticles can deliver a broad range of therapeutic payloads to atherosclerotic lesions. These nanoparticles can suppress pro-atherogenic macrophage processes, leading to improved resolution of inflammation and stabilization of plaques. Finally, we propose future opportunities for novel diagnostic and therapeutic strategies and provide solutions to challenges in this area for the purpose of accelerating the clinical translation of nanomedicine for the treatment of atherosclerotic vascular disease. In this Review, Tao and colleagues discuss the latest advances in nanoparticle-based imaging and therapeutic approaches targeting macrophages in atherosclerotic plaques, highlight opportunities for novel macrophage-targeting nanomedicines for atherosclerosis diagnosis and treatment, and provide solutions to challenges in this area to accelerate clinical translation. Because macrophages have key roles in atherosclerosis progression, macrophage-mediated pro-atherosclerotic processes are important targets for both diagnostic imaging and novel therapies for atherosclerosis. Nanotechnology is particularly advantageous in its capacity to substantially improve the pharmacokinetic profile and chemical stability of encapsulated diagnostic and therapeutic agents for atherosclerosis management. The rational design of nanoparticle-based imaging agents that can specifically target inflammatory macrophages in atherosclerotic plaques offers diagnostic potential to non-invasively quantify atherosclerosis plaque burden, evaluate the efficacy of medical interventions and serve as surrogate end points. Targeted nanotherapeutics that can modulate plaque macrophage functions by the activation or suppression of specific signalling pathways have shown great promise in preclinical models by improving therapeutic efficacy and reducing off-target and systemic adverse effects. Rapid advances in nanotechnology and bioengineering and an improved understanding of atherosclerotic pathophysiology have accelerated the development of novel nanotherapeutics for atherosclerosis diagnosis and treatment. The success of various nanomedicine-based approaches in preclinical studies of atherosclerosis and their use in human cancer bode well for their future application in the diagnosis and treatment of patients with cardiovascular disease.
登录
查看更多内容
影响因子：
15
作者：
Chen, Wei;Cheng, Chi-An;Sletten, Ellen M.
通讯作者：
Sletten, Ellen M.
影响因子：
46.2
作者：
Behzadi S;Serpooshan V;Tao W;Hamaly MA;Alkawareek MY;Dreaden EC;Brown D;Alkilany AM;Farokhzad OC;Mahmoudi M
通讯作者：
Mahmoudi M
使用针对凋亡巨噬细胞的双模态单光子发射计算机断层扫描/磁共振成像探针检测易损动脉粥样硬化斑块
影响因子：
9.5
作者：
Cheng, Dengfeng;Li, Xiao;Shi, Hongcheng
通讯作者：
Shi, Hongcheng
影响因子：
17.1
作者：
Beldman TJ;Senders ML;Alaarg A;Pérez-Medina C;Tang J;Zhao Y;Fay F;Deichmöller J;Born B;Desclos E;van der Wel NN;Hoebe RA;Kohen F;Kartvelishvily E;Neeman M;Reiner T;Calcagno C;Fayad ZA;de Winther MPJ;Lutgens E;Mulder WJM;Kluza E
通讯作者：
Kluza E
影响因子：
17.1
作者：
Beldman, Thijs J.;Malinova, Tsveta S.;Kluza, Ewelina
通讯作者：
Kluza, Ewelina